• Amylyx Pharmaceuticals recently reported that 24-week and 48-week results from its Phase 2 open-label HELIOS trial of AMX0035 in adults with Wolfram syndrome were published in The Journal of Clinical Investigation, showing sustained improvements in beta cell function, glycemic control and disease stabilization with a mild to moderate safety profile.
• Beyond the clinical data, qualitative interviews highlighted patient-reported improvements in diabetes and vision problems, underscoring the potential real-world impact of AMX0035 in a rare disorder with no approved treatments.
• We will now examine how these peer-reviewed HELIOS results and patient-reported benefits may influence Amylyx Pharmaceuticals’ broader rare disease investment narrative.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Amylyx Pharmaceuticals Investment Narrative Recap

To own Amylyx, you need to believe avexitide can become the first approved treatment for post bariatric hypoglycemia while the broader rare disease pipeline matures. The HELIOS publication adds credibility to AMX0035 and the neurodegeneration story, but it does not change that the LUCIDITY Phase 3 readout in Q3 2026 remains the key near term catalyst and that a disappointing result there is still the biggest risk.

The most relevant recent announcement alongside HELIOS is the March 2026 update that LUCIDITY has fully randomized its last participant, locking in a clear path to top line PBH data. Together, a de‑risking avexitide program and peer‑reviewed AMX0035 Wolfram data strengthen Amylyx’s rare disease narrative, but they also increase the importance of managing clinical and funding risk as the company remains loss making with US$317,000,000 in cash.

Yet investors should also weigh how much depends on LUCIDITY succeeding, given that...

Amylyx Pharmaceuticals' narrative projects $107.8 million revenue and $23.1 million earnings by 2029. This requires earnings to increase by about $167.8 million from -$144.7 million today.

Uncover how Amylyx Pharmaceuticals' forecasts yield a $22.20 fair value, a 58% upside to its current price.

Exploring Other Perspectives

While consensus focuses on LUCIDITY risk, the most optimistic analysts, who once modeled US$459,000,000 revenue and US$41,400,000 earnings by 2029, might now revisit those assumptions in light of HELIOS and the possibility that AMX0035’s progress could reshape how diversified Amylyx’s story really is.

Explore 3 other fair value estimates on Amylyx Pharmaceuticals - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amylyx Pharmaceuticals research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Amylyx Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amylyx Pharmaceuticals' overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.